Marijean M Miller1, Mary E Revenis2, Michael M Lai3, Annal D Meleth4, Elaine S Jeffress4, Ana Carrera4, Yao I Cheng5, Ann M Sill5, Robert McCarter6. 1. Department of Ophthalmology, Children's National Medical Center and The George Washington University, Washington, DC; Department of Pediatrics, Children's National Medical Center and The George Washington University, Washington, DC. Electronic address: mmiller@childrensnational.org. 2. Department of Pediatrics, Children's National Medical Center and The George Washington University, Washington, DC. 3. The Retina Group of Washington, Washington, DC; Department of Ophthalmology, Georgetown University, Washington, DC. 4. Department of Ophthalmology, Children's National Medical Center and The George Washington University, Washington, DC. 5. Division of Biostatistics and Study Methodology, Children's National Medical Center, Washington, DC. 6. Division of Biostatistics and Study Methodology, Children's National Medical Center, Washington, DC; Biostatistics and Epidemiology, The George Washington University, Washington, DC.
Abstract
PURPOSE: To characterize the retinopathy of prematurity (ROP) and survival of infants born at gestational age (GA) of 22-25 weeks. METHODS: This study was a comparative case series for the total set of 78 infants ≤25 GA screened for ROP at a level IV NICU during a 21-month period. Data are presented on infants screened for ROP from 6 weeks after birth for 22 and 23 weeks' GA infants and from 5 weeks after birth for 24 and 25 weeks' GA. Accounting for the competing risk of mortality, we implemented Cox CR regression models to assess birth weight, GA, and admission diagnosis as potential risk factors for the following time to event outcomes: type 1 disease, aggressive posterior ROP (AP-ROP), plus disease, first presentation of ROP, and worst ROP observed. RESULTS: Risk of laser treatment (subhazard ratio [SHR] = 0.56, P = 0.007) and of plus disease (SHR = 0.49, P = 0.001) was increased among those born at lower GA. Twenty infants required laser for type 1 disease at median postmenstrual age (PMA) of 35.8 weeks (range, 33.0-42.7); infants with AP-ROP had laser at PMA of 34.5 weeks (range, 33.0-36.9), 2 weeks earlier than infants without AP-ROP at PMA 36.5 weeks (range, 33.9-42.7). The cumulative probability of receiving laser therapy approached 46% (22 or 23 weeks' GA), 30% (24 weeks' GA), and 18% (25 weeks' GA). CONCLUSIONS: The 2013 screening guidelines appear to be appropriate for infants of 22 and 23 weeks' GA when ROP screening begins at PMA 31 weeks.
PURPOSE: To characterize the retinopathy of prematurity (ROP) and survival of infants born at gestational age (GA) of 22-25 weeks. METHODS: This study was a comparative case series for the total set of 78 infants ≤25 GA screened for ROP at a level IV NICU during a 21-month period. Data are presented on infants screened for ROP from 6 weeks after birth for 22 and 23 weeks' GA infants and from 5 weeks after birth for 24 and 25 weeks' GA. Accounting for the competing risk of mortality, we implemented Cox CR regression models to assess birth weight, GA, and admission diagnosis as potential risk factors for the following time to event outcomes: type 1 disease, aggressive posterior ROP (AP-ROP), plus disease, first presentation of ROP, and worst ROP observed. RESULTS: Risk of laser treatment (subhazard ratio [SHR] = 0.56, P = 0.007) and of plus disease (SHR = 0.49, P = 0.001) was increased among those born at lower GA. Twenty infants required laser for type 1 disease at median postmenstrual age (PMA) of 35.8 weeks (range, 33.0-42.7); infants with AP-ROP had laser at PMA of 34.5 weeks (range, 33.0-36.9), 2 weeks earlier than infants without AP-ROP at PMA 36.5 weeks (range, 33.9-42.7). The cumulative probability of receiving laser therapy approached 46% (22 or 23 weeks' GA), 30% (24 weeks' GA), and 18% (25 weeks' GA). CONCLUSIONS: The 2013 screening guidelines appear to be appropriate for infants of 22 and 23 weeks' GA when ROP screening begins at PMA 31 weeks.
Authors: Nader Sheibani; Ismail S Zaitoun; Shoujian Wang; Soesiawati R Darjatmoko; Andrew Suscha; Yong-Seok Song; Christine M Sorenson; Victor Shifrin; Daniel M Albert; Ignacio Melgar-Asensio; Irawati Kandela; Jack Henkin Journal: Exp Eye Res Date: 2020-04-06 Impact factor: 3.467
Authors: Rolf F Maier; Helmut Hummler; Ulrich Kellner; Tim U Krohne; Burkhard Lawrenz; Birgit Lorenz; Barbara Mitschdörfer; Claudia Roll; Andreas Stahl Journal: Ophthalmologie Date: 2022-05-04
Authors: Pia Lundgren; Lena Jacobson; Anna-Lena Hård; Abbas Al-Hawasi; Eva Larsson; Lotta Gränse; Marie Saric; Birgitta Sunnqvist; Kristina Tornqvist; Agneta Wallin; Gerd E Holmstrom; Lois LE Smith; Eva Morsing; Ann Hellström Journal: BMJ Open Ophthalmol Date: 2021-04-21
Authors: Rolf F Maier; Helmut Hummler; Ulrich Kellner; Tim U Krohne; Burkhard Lawrenz; Birgit Lorenz; Barbara Mitschdörfer; Claudia Roll; Andreas Stahl Journal: Ophthalmologe Date: 2021-03-10 Impact factor: 1.059